Medicus Pharma (MDCX) to acquire Antev Ltd. in share exchange; up to $65M in milestones

Medicus Pharma Ltd.

Consideration: 2,666,600 Medicus shares (~19% stake) plus up to US$65M contingent on FDA Phase 2/NDA approvals.
Antev's lead asset Teverelix is a next-generation GnRH antagonist targeting acute urinary retention recurrence and high-CV-risk prostate cancer.
Combined market opportunity estimated at ~$6B annually ($2B AUR, $4B prostate cancer).
Transaction expected to close by end of June 2025, subject to due diligence, definitive agreement, and regulatory approvals.
Antev shares subject to 9-month staggered lock-up and 36-month voting rights in favor of Medicus management.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.